

Helicobacter pylori Infection among Patients with Dyspepsia and Intrafamilial Transmission

¹Mustafa Yalçın, ²Ayla Yalçın, ¹Göksel Bengi, ²Selim G Nak

¹Department of Gastroenterology, Dokuz Eylul University Medical Faculty, Ege, Turkey, ²Department of Gastroenterology, Uludağ University Medical Faculty, Bursa, Turkey.

ABSTRACT

Introduction: Recurrence is an important problem after *Helicobacter pylori* infection, and intrafamilial transmission has an important role in recurrence. In this study, we aimed to investigate the significance of intrafamilial transmission for recurrence development after treatment as well as its usefulness in prevention.

Materials and methods: Of the 109 patients who had dyspepsia and underwent endoscopy, 74 patients had *H. pylori* infection and were enrolled in this study. Infected family members were also detected. Patients were randomly divided into groups I and II, with each group containing 37 individuals. In group I, patients and their infected family members were treated together at the same time. In group II, only the patients were treated. Treatment success was evaluated at the 1st month and evaluation for recurrence was carried out at the 6th month.

Results: *Helicobacter pylori* infection was detected in 67.8% of the patients with dyspepsia. Two patients in each group did not show up at the 1st month control. Eradication was achieved in 63 of the 70 patients (90.0%) who completed their treatment. After 6 months, patients with successful treatment had no recurrence in any of the 32 patients in group I. There were recurrence in 3 of the 31 patients (9.7%) in group II; however, there was no statistically significant difference between the groups ($p = 0.113$).

Conclusion: Our study showed that eradication treatment in patients and family members with *H. pylori* infection resulted in a decrease in the number of recurrences even though it was not statistically significant.

Keywords: Dyspepsia, Eradication, *Helicobacter pylori*, Intrafamilial transmission, Recurrence.

How to cite this article: Yalçın M, Yalçın A, Bengi G, Nak SG. *Helicobacter pylori* Infection among Patients with Dyspepsia and Intrafamilial Transmission. Euroasian J Hepato-Gastroenterol 2016;6(2):93-96.

Source of support: Nil

Conflict of interest: None

Copyright and License information: Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd. This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/3.0/>

INTRODUCTION

Helicobacter pylori is a bacterial pathogen that causes gastroduodenal inflammation leading to gastric and duodenal ulcers and atrophic gastritis.¹ It is responsible for one of the most common infections worldwide; nearly half of the world's population harbor the microorganism.² *Helicobacter pylori* infections are generally acquired during childhood via intrafamilial or "mother to child" transmission. *Helicobacter pylori* infection is five times more prevalent in children of infected mothers. *Helicobacter pylori* infections are usually acquired during childhood and more than one strain can colonize in the stomach at this stage. While most of these strains are spontaneously eradicated, one genotype that adapts gastric mucosa and

host immune system can permanently colonize in the host.³ Intrafamilial transmission, low socioeconomic status, and poor hygienic conditions contribute to the high prevalence of infection.^{4,5}

Prevalence and incidence of *H. pylori* infection in gastric mucosa differ between countries, depending on the developmental state and age. While its prevalence varies between 60 and 85% in developing countries, this rate has been reduced down to 10 to 30% in developed countries owing to emphasis on personal hygiene and successful eradication practices.⁶

Recurrence development after the treatment of *H. pylori* is frequent, especially in developing and underdeveloped countries. Annual recurrence rate is 1% in developed countries, whereas this rate reaches up to

Address reprint requests to: Göksel Bengi, Department of Gastroenterology, Dokuz Eylul University Medical Faculty, Ege, Turkey
Phone: +902324123701, e-mail: drgekseibengi@hotmail.com

30 to 40% in developing countries. Intrafamilial transmission is a known contributor in those high recurrence rates. However, whether infected family members should be treated is still a subject of debate. In this study, we tried to seek answers to these questions.

MATERIALS AND METHODS

One hundred and nine patients who presented to outpatient of Department of Gastroenterology, Uludağ University Faculty of Medicine with complaints of dyspepsia were informed about the study, and after obtainment of their consent, they were included in the study. Upper gastrointestinal system endoscopy (UGISE) was performed in all patients. *Helicobacter pylori* was detected with rapid urease test [Campylobacter-like organism (CLO) test/Delta Western/Australia]. Patients who were infected with *H. pylori* were enrolled in the study for initiation of eradication treatment. Patients were followed up for 6 months.

Study inclusion criteria were as follows: (1) Patients presenting to outpatient clinic with complaints of dyspepsia, (2) patients who have *H. pylori* infection, (3) patients who are living together with at least three family members for at least 2 years, and (4) adult patients over the age of 18.

Study exclusion criteria were as follows: (1) Patients in whom dyspeptic symptoms are associated with an organic disease other than ulcer and gastritis, such as pancreatic pathologies, gallbladder disease etc., (2) history of previous stomach operation, and (3) pregnancy.


Anamnesis, physical examination, UGISE, rapid urease test during endoscopy, blood tests (hemogram, erythrocyte sedimentation rate, AST, ALT, sodium, potassium, fasting blood glucose, urea, and creatinine), and upper abdominal ultrasonography were performed in all patients. Patients enrolled in the study were randomly divided into groups I and II. In all patients and in family members of patients in group I, the following treatment was administered which represent the most common eradication treatment regime: Lansoprazol 30 mg twice a day, Amoxicillin 1 mg twice a day, and Clarithromycin 500 mg twice a day. The triple therapy was administered for a duration of 14 days.

Whether family members were infected with *H. pylori* was detected with stool antigen test. Premier Platinum HpSA brand stool antigen test was used in the study. The specimens were tested in Uludağ University Microbiology and Infectious Diseases Laboratory.

Study groups were as follows:

Group I: Patients and their infected family members living together with the patient were treated together at the same time.

Group II: Only the patients were treated. Patients were evaluated for eradication success 1 month after completion of



treatment and for development of recurrence 6 months after treatment with stool antigen test. Treated family members were not followed up for recurrence development. Based on these data, it was aimed to seek answers to the following questions: Does intrafamilial transmission has significance in recurring cases of *H. pylori* infection? Is it necessary to treat infected family members of *H. pylori* infected cases? Study plan is shown in Flow Chart 1.

Statistical Analysis

Statistical analyses were carried out using Statistical Package for the Social Sciences (SPSS) 15.0 computer software (SPSS Inc., Software Chicago, IL, USA). Differences between groups were analyzed using Mann–Whitney U test, Pearson’s chi-square test, and Fisher’s exact chi-square test. p-value < 0.05 was accepted as being statistically significant.

RESULTS

Patients underwent UGISE, and rapid urease test (CLO) was performed. Seventy-four patients (67.8%) were infected with *H. pylori* and enrolled in the study (Table 1). Seventy-four patients (25 men, 49 women) who met the inclusion criteria were randomly divided into two groups.

Group I: *Helicobacter pylori* infected family members of the 37 patients in this group were detected with stool antigen test, and they received eradication treatment together with the patients.

Table 1: Frequency of *H. pylori* in patients with dyspepsia

	Number	%
CLO test (+)	74	67.8
CLO test (-)	35	32.2
Total	109	100

CLO: Campylobacter-like organism



Group II: Eradication treatment was administered in 37 patients in this group. Family members were not treated.

Demographical properties in each group are presented in Table 2. Mean ages were 40.6 ± 13.76 years in group I and 40.5 ± 9.75 years in group II. There was no statistically significant difference between groups according to Pearson's chi-square method ($p = 0.367$). Most of our patients were determined to have moderate to good socioeconomic state. The findings in UGISE are presented in Table 3. Both groups had similar frequencies of stomach ulcers, whereas there were more duodenal ulcers, gastritis, and sliding hernia in group I. There were esophagitis in 10 patients in group I and in 9 patients in group II. Number of family members living together with the patients in groups I and II were determined (Table 4). Totally 125 family members were determined in group I. Twenty-six individuals (26%) were spouses of patients, 99 individuals consisted of children, parents, grandchildren, and daughter-in-law. There were 119 family members in group II, 34 of them (28.5%) were spouses of patients, and 85 individuals consisted of others (Table 4). Stool antigen test results of family members are presented in Table 5. In group I, 34 of the 125 individuals (27.2%) were infected with *H. pylori*; in group II, 34 of the 115 individuals (28.5) were infected. When the spouses were evaluated, 9 individuals in group I and 10 individuals in

Table 2: Demographical properties of patients

	Group I	Group II
Number of cases	37	37
Age (mean) (years)	40.6 ± 13.76	40.5 ± 9.75
Female	22	27
Male	15	10
Good socioeconomic status	15	17
Moderate socioeconomic status	19	20
Poor socioeconomic status	3	0

Table 3: Findings in upper gastrointestinal system endoscopy

	Group I	Group II	Total
Stomach ulcer	1	1	2
Duodenal ulcer	5	3	8
Gastritis	14	10	24
Gastroesophageal reflux	10	9	19
Sliding hiatal hernia	4	2	6
Normal	5	13	18
Total	37	37	74

Table 4: Family members in groups living together with the patient

	Group I	Group II	Total
Spouse	26	34	60
Others	99	85	184
Total	125	119	244

Table 5: Number of family members and stool antigen test results

	Group I		Group II		Total
	H. p (+)	H. p (-)	H. p (+)	H. p (-)	
Spouse	9	17	10	24	60
Others	25	74	24	61	184
Total	34	91	34	85	244

H. p: *Helicobacter pylori*

Table 6: Stool antigen test results of the patients at 1st and 6th months after treatment

	Group I		Group II		Total
	H. p (+)	H. p (-)	H. p (+)	H. p (-)	
1st month	3	32	4	31	70
6th month	0	32	3	28	63

H. p: *Helicobacter pylori*

group II were infected with *H. pylori* ($p = 0.614$). When all patients were evaluated as a whole, prevalence of *H. pylori* infection was found as 27.8%.

Following a treatment for 14 days, patients were called for assessment at 1st month. Two patients in each group did not continue with the study, so the study continued with 35 patients in each group. *H. pylori* eradication was evaluated with stool antigen test. Treatment was unsuccessful in 3 patients in group I (8.57%) and in 4 patients in group II (11.4%). Eradication success was determined as 90% in all patients.


Patients were called for evaluation again at the 6th month. According to evaluation of recurrence with repeat stool antigen test for *H. pylori*, there was no recurrence in group I, and there was recurrence in 3 patients in group II (9.7%). There was no significant difference between the two groups according to Fisher's exact chi-square test ($p = 0.113$) (Table 6). The outcome of the study has been summarized in Flow Chart 2.

DISCUSSION

More than 50% of the world population is believed to be infected with *H. pylori* today. The prevalence is about 5 to 10% in developed countries, whereas this rate reaches up to 70 to 90%, and even 100% in certain age groups in underdeveloped and developing countries.^{3,7,8} Geographical distribution of the infection is closely associated with socioeconomic status. There are even differences in seroprevalence between different races in developed countries. As an interesting difference, *H. pylori* infection incidence is high in childhood age in developing countries. In developed countries, prevalence of *H. pylori* in childhood age is low, and the prevalence increases with age. The peak level almost never exceeds 50% in these countries.⁹

Turkey has a resemblance to developing countries in terms of *H. pylori* prevalence. However, although, i.e.,

Flow Chart 2: Study plan and findings



what the individual studies indicate, general prevalence of *H. pylori* infection in Turkey is not exactly known. Studies investigating *H. pylori* presence in selected patient groups with invasive methods report its prevalence between 41 and 96%.¹⁰ In our study, we determined *H. pylori* prevalence in patients with dyspepsia in Bursa as 67.8%. This result is consistent with the results of previous epidemiological studies.

Helicobacter pylori can be detected in stool, vomit, and sputum, and infection is possibly transmitted via oral to oral, fecal to oral, and gastro to oral routes. Major source of transmission appears to be intrafamilial.^{4,5} Especially mother is the major source of infection at childhood age, while spouses are the major source in adulthood. In areas with high infection rates, *H. pylori* infection appears to be preventable by eradication in family members.¹¹⁻¹³ Based on these reports, we thought we could reduce recurrences if we treated family members in order to prevent intra-familial transmission.

We divided 74 patients infected with *H. pylori* randomly into two groups. In both groups, we detected whether family members living together with the patient were infected with *H. pylori*. In group I, we administered eradication treatment to patients together with the infected family members. In group II, we treated the patients only. We evaluated treatment success at the 1st month and recurrence rates at the 6th month using stool antigen test. Eradication success for *H. pylori* was 90% at 1st month in

our study. At the 6th month, there was no recurrence in group I, and there were recurrences in 3 patients (9.7%) in group II. There was no statistically significant difference between the two groups according to Fisher's exact test ($p = 0.113$). However, administering eradication treatment to family members decreased recurrences.

Our study showed that eradication treatment in patients and family member with *H. pylori* infection resulted in a decrease in the number of recurrences which was not statistically significant. However, since the number of recurrences will increase in the long-term follow-up, we think the treatment of infected family members is necessary.

REFERENCES

- Cardenas VM, Mulla ZD, Ortiz M, Graham DY. Iron deficiency and *Helicobacter pylori* infection in the United States. *Am J Epidemiol* 2006 Jan;163(2):127-134.
- Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med* 2002 Oct;347(15):1175-1186.
- Alarcon T, Martinez MJ, Urruzuno P, Cilleruelo ML, Madruga D, Sebastian M, Domingo D, Sanz JC, Lopez-Brea M. Prevalence of CagA and VacA antibodies in children with *Helicobacter pylori*-associated peptic ulcer compared to prevalence in pediatric patients with active or nonactive chronic gastritis. *Clin Diagn Lab Immunol* 2000 Sep;7(5):842-844.
- Brown LM. *Helicobacter pylori*: epidemiology and routes of transmission. *Epidemiol Rev* 2000;22(2):283-297.
- Czinn SJ. *Helicobacter pylori* infection: detection, investigation, and management. *J Pediatr* 2005 Mar;146(3):21-26.
- Singh M, Prasad KN, Yachha SK, Saxena A, Krishnani N. *Helicobacter pylori* infection in children: prevalence, diagnosis and treatment outcome. *Trans R Soc Trop Med Hyg* 2006 Mar;100(3):227-233.
- Kersulyte D, Mukhopadhyay AK, Velapatiño B, Su W, Pan Z, Garcia C, Hernandez V, Valdez Y, Mistry RS, Gilman RH, et al. Differences in genotypes of *Helicobacter pylori* from different human populations. *J Bacteriol* 2000 Jun;182(11):3210-3218.
- Goosen C, Theron J, Ntsala M, Maree FF, Olckers A, Botha SJ, Lastovica AJ, van der Merwe SW. Evaluation of a novel heminested PCR assay based on the phosphoglucosamine mutase gene for detection of *Helicobacter pylori* in saliva and dental plaque. *J Clin Microbiol* 2002 Jan;40(1):205-209.
- Kikuchi S, Dore MP. Epidemiology of *Helicobacter pylori* infection. *Helicobacter* 2005;10 (Suppl 1):1-4.
- Kadayıfci A, Buyukhatipoglu H, Cemil Savas M, Simsek I. Eradication of *Helicobacter pylori* with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. *Clin Ther* 2006 Nov;28(11):1960-1966.
- Brenner H, Rothenbacher D, Bode G, Dieudonne P, Adler G. Active infection with *Helicobacter pylori* in healthy couples. *Epidemiol Infect* 1999 Feb;122(1):91-95.
- Fujimoto Y, Furusyo N, Toyoda K, Takeoka H, Sawayama Y, Hayashi J. Intra familial transmission of *Helicobacter pylori* among the population of endemic areas in Japan. *Helicobacter* 2007 Apr;12(2):170-176.
- Brown LM, Thomas TL, Ma JL, Chang YS, You WC, Liu WD, Zhang L, Pee D, Gail MH. *Helicobacter pylori* infection in rural China: demographic, lifestyle and environmental factors. *Int J Epidemiol* 2002 Jun;31(3):638-645.